Bone Biologics 10-Q: Cash Runway to Q2 2027, But Nasdaq MVLS Delisting Risk Emerges
BBLG is trading near its 52-week low of $0.62 (5.6% above the low).
Summary
Bone Biologics' 10-Q confirms the July private placement extended cash runway into Q2 2027, but a new Nasdaq listing rule threatens delisting if the company cannot maintain a $5 million market value.
Key Events · Earnings and Guidance · BBLG
-
Going Concern Warning Reiterated
The company reported a net loss of $1.5 million and used $1.3 million in operating cash for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern.
-
Cash Runway Extended to Q2 2027
The July 2026 private placement provided net proceeds of approximately $2.7 million, and available cash including the placement is expected to fund operations into the second quarter of 2027.
-
Nasdaq MVLS Delisting Risk
The SEC approved Nasdaq Listing Rule 5550(a)(6) requiring a $5 million market value of listed securities on July 22, 2026, but the order was stayed on July 29, 2026. The company is not in compliance with the MVLS Requirement if it comes into effect, and could be delisted after 30 consecutive business days of non-compliance.
-
Pre-Funded Warrant Exercises
Through August 14, 2026, 945,677 pre-funded warrants from the July 2026 Private Placement were exercised for proceeds of $945.
Analysis · BBLG · Industrial Applications And Services
Bone Biologics reported a net loss of $1.5 million for the first half of 2026 and reiterated its going concern warning. The July 2026 private placement extended cash runway into Q2 2027, but the company now faces a new Nasdaq delisting risk under the MVLS Requirement, which could suspend trading if the rule takes effect and the company fails to meet the $5 million market value threshold for 30 consecutive business days.
At the time of this filing, BBLG was trading at $0.66 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.62 to $4.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.